^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIM1 mutation

    i
    Other names: PIM1, Pim-1 Proto-Oncogene, Serine/Threonine Kinase, Serine/Threonine-Protein Kinase Pim-1, Proto-Oncogene Serine/Threonine-Protein Kinase Pim-1, Pim-1 Oncogene (Proviral Integration Site 1), Pim-1 Kinase 44 KDa Isoform, Pim-1 Oncogene, Oncogene PIM1, PIM
    Entrez ID:
    5292
    Related biomarkers:
    Expression
    1year
    Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study. (PubMed, Hematol Oncol)
    While 12-month PFS failed to reach statistical significance, subgroup analyses favor Pola-R-CHP. Further research with a wider population, longer follow-up, and screening of advantageous groups are warranted.
    Retrospective data • Journal • Real-world evidence • IO biomarker • Real-world
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • KMT2D (Lysine Methyltransferase 2D) • PIM1 (Pim-1 Proto-Oncogene) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    TP53 mutation • PIM1 mutation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq)
    1year
    High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics. (PubMed, Am J Hematol)
    Frequent oncogenic PIM1 mutations were present in adult HGBCL, NOS. In vitro analyses with pharmacologic or genetic inhibition of PIM1 expression triggered B-cell activation and NF-κB-induced apoptosis, suggesting that PIM1 is a rational therapeutic target.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • CARD11 (Caspase Recruitment Domain Family Member 11) • GNA13 (G Protein Subunit Alpha 13) • PIM1 (Pim-1 Proto-Oncogene) • CCND3 (Cyclin D3) • PRDM1 (PR/SET Domain 1) • DDX3X (DEAD-Box Helicase 3 X-Linked)
    |
    PIM1 mutation
    1year
    Analysis of Therapeutic Efficacy and Adverse Prognostic Factors of Secondary Central Nervous System Lymphoma (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    HD-MTX combined with TMZ as the first-line strategy may improve patient prognosis, and early application of gene sequencing is beneficial for evaluating prognosis.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • PIM1 (Pim-1 Proto-Oncogene) • BTG2 (BTG Anti-Proliferation Factor 2) • TBL1XR1 (TBL1X Receptor 1)
    |
    HER-2 mutation • PIM1 mutation
    |
    methotrexate IV
    over1year
    Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement. (PubMed, Virchows Arch)
    In conclusion, both BCL6-R-positive FL and BCL6-R-positive DLBCL had a common mutational profile; but also, differences. DLBCL cases had a higher density of microenvironment markers.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • CD163 (CD163 Molecule) • ARID1B (AT-Rich Interaction Domain 1B) • CD36 (thrombospondin receptor) • IL10 (Interleukin 10) • RHOA (Ras homolog family member A) • PIM1 (Pim-1 Proto-Oncogene) • CSF1R (Colony stimulating factor 1 receptor) • HLA-B (Major Histocompatibility Complex, Class I, B) • H1-4 (H1.4 Linker Histone, Cluster Member) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BTG2 (BTG Anti-Proliferation Factor 2) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    |
    ATM mutation • MYD88 L265P • BCL6 rearrangement • ARID1B mutation • IL10-L • PIM1 mutation • MYC negative
    almost2years
    The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis. (PubMed, Medicine (Baltimore))
    The multivariate analysis observed the association between high lactate dehydrogenase value and the immunohistochemical expression of PIM1 or with the mutant status of the PIM1 gene representing negative prognostic factors (HR = 2.066, P = .042, respectively HR = 3.100, P = .004). In conclusion, our preliminary data suggest that the oncogenic mutations of PIM1 and MYD88 in our DLBCL cohort may improve the diagnosis and prognosis of DLBCL patients in an advanced stage.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PIM1 (Pim-1 Proto-Oncogene)
    |
    MYD88 mutation • PIM1 mutation
    almost2years
    Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. (PubMed, World J Clin Oncol)
    Our empirical observations demonstrated that the combination of zanubrutinib with HD-MTX yielded a marked clinical response and tolerability among newly diagnosed PCNSL patients. Non-invasive CSF liquid biopsy profiling may be feasible for evaluating treatment response and tumor burden.
    Clinical data • Journal • Combination therapy
    |
    PIM1 (Pim-1 Proto-Oncogene)
    |
    PIM1 mutation
    |
    Brukinsa (zanubrutinib) • methotrexate • methotrexate IV
    2years
    RCHOP Plus High-Dose Methotrexate As First-Line Therapy in Large B-Cell Lymphoma with Testis Involvement (ASH 2023)
    PTL may benefit from HD-MTX in preventing relapse, while alternative treatments should be explored for DLBCL-T. Future studies should consider PTL and DLBCL-T as separate entities to better understand their characteristics and optimize treatment strategies.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CD79B (CD79b Molecule) • B2M (Beta-2-microglobulin) • CREBBP (CREB binding protein) • CARD11 (Caspase Recruitment Domain Family Member 11) • EP300 (E1A binding protein p300) • TCF3 (Transcription Factor 3) • PIM1 (Pim-1 Proto-Oncogene) • IRF4 (Interferon regulatory factor 4) • CD58 (CD58 Molecule) • PRDM1 (PR/SET Domain 1) • NFKBIE (NFKB Inhibitor Epsilon)
    |
    PD-L1 expression • MYD88 mutation • MYD88 L265P • PD-1 expression • BCL2 expression • MYC expression • CD79B mutation • PIM1 mutation
    |
    Rituxan (rituximab) • methotrexate IV
    2years
    The genetic landscape of histologically transformed marginal zone lymphomas. (PubMed, Cancer)
    The current findings reveal the clinicopathologic and genetic features of HT-MZLs, suggesting that these tumors might constitute a group distinct from MZL and de novo non-GCB type DLBCL. TBL1XR1 mutations may be considered a predictor of HT in MZL.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CARD11 (Caspase Recruitment Domain Family Member 11) • PIM1 (Pim-1 Proto-Oncogene) • CCND3 (Cyclin D3) • IRF4 (Interferon regulatory factor 4) • ID3 (Inhibitor Of DNA Binding 3, HLH Protein) • TBL1XR1 (TBL1X Receptor 1)
    |
    MYC expression • MYC rearrangement • BCL6 rearrangement • PIM1 mutation
    2years
    High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study (ASH 2023)
    The novel induction treatment of MIT achieved encouraging responses in newly diagnosed PCNSL patients with acceptable toxicities. The early clearance of ctDNA in CSF may be related to favorable survival.
    Clinical • P2 data
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • PIM1 (Pim-1 Proto-Oncogene) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    MYD88 mutation • PIM1 mutation
    |
    Imbruvica (ibrutinib) • temozolomide • methotrexate IV
    2years
    PIM1 Point Mutations Increase Migration of Diffuse Large B-Cell Lymphoma (DLBCL) Cells (ASH 2023)
    PIM1 mutations did not affect the proliferation of DLBCL cells and did not increase resistance to doxorubicin, excluding the proliferation rate or treatment resistance as a cause of the poor prognosis associated with PIM1 mutations...Finally, in transwell assays, PIM1 mutant cells exhibited markedly increased migratory potential. Taken together, these studies indicate that PIM1 mutants are not likely associated with differential drug responses, but rather facilitate tumor dissemination and are thus associated with inferior prognosis in DLBCL patients harboring PIM1 mutations.
    Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IFNG (Interferon, gamma) • CD79B (CD79b Molecule) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIM1 (Pim-1 Proto-Oncogene) • IL15 (Interleukin 15)
    |
    MYD88 mutation • MYD88 L265P • CD79B mutation • CD79B mutation • PIM1 mutation • MYD88 mutation + CD79B mutation
    |
    doxorubicin hydrochloride
    2years
    Landscape of BCL11B mutations in Human Cancer (AMP 2023)
    Our report represents one of the most extensive and detailed studies regarding the landscape of BCL11B point and indel mutations in human cancer. BCL11B alterations occur widely in mature, immature, B-cell, Tcell, and sarcomatous malignancies. TP53, PIM1, and SOCS1 are the most commonly co-mutated genes.
    TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • PIM1 (Pim-1 Proto-Oncogene) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    PIM1 mutation • BCL11B mutation
    |
    FoundationOne® Heme CDx